Author: admin

Medicines360 and Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing and LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Placement

by admin

Medicines360, a nonprofit global women’s health pharmaceutical company, and Allergan, plc (NYSE: AGN), a leading global pharmaceutical company, today announced the publication of, “A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement” in the November, 2016 medical journal, American Journal of Obstetrics & Gynecology.

  • Posted in Press Releases
  • Comments Off on Medicines360 and Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing and LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Placement

[American Journal of Obstetrics & Gynecology] A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement

by admin

  • Posted in Publications
  • Comments Off on [American Journal of Obstetrics & Gynecology] A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement

[Journal of Contraception] Levonorgestrel release rates over five years with the Liletta™ 52 mg intrauterine system

by admin

  • Posted in Publications
  • Comments Off on [Journal of Contraception] Levonorgestrel release rates over five years with the Liletta™ 52 mg intrauterine system

Medicines360 and Population Services International Announce New Partnership to Expand Access to Hormonal IUDs to Women in Africa

by admin

Medicines360, a global nonprofit pharmaceutical company, and Population Services International (PSI), a leading global health organization working in reproductive health, announced today an agreement to expand access to Medicines360’s hormonal intrauterine device (IUD) (levonorgestrel-releasing intrauterine system) 52 mg.

  • Posted in Press Releases
  • Comments Off on Medicines360 and Population Services International Announce New Partnership to Expand Access to Hormonal IUDs to Women in Africa

Allergan and Medicines360 Announce Donation of Intrauterine Devices (IUD) to the Centers for Disease Control (CDC) Foundation to Help Address Microcephaly Impact from Zika Virus in Puerto Rico

by admin

Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that they will donate 10,000 units of their hormonal IUD, LILETTA®.

  • Posted in Press Releases
  • Comments Off on Allergan and Medicines360 Announce Donation of Intrauterine Devices (IUD) to the Centers for Disease Control (CDC) Foundation to Help Address Microcephaly Impact from Zika Virus in Puerto Rico

Could The Most Effective Birth Control Soon Become The Cheapest?

by admin

The most effective reversible forms of birth control are mostly priced out of reach for millions of women who need it most—until now. An unusual partnership between a nonprofit pharmaceutical company and a traditional pharmaceutical distributor aims to increase access to IUDs (intrauterine devices) for U.S. servicewomen and in public clinics.

  • Posted in News
  • Comments Off on Could The Most Effective Birth Control Soon Become The Cheapest?